在减少囊性纤维化 (CF) 恶化和改善精选的螺旋测量参数的CFTR调节器治疗效率:在单个中心波兰人群中的现实研究
Hanna M Winiarska1, Daria Springer1, Filip Wojtaś1
1Department of Pulmonology, Allergology and Pulmonary Oncology, Poznan University of Medical Sciences, 84 Szamarzewskiego St, 60-569 Poznań, Poland.
Journal of clinical medicine
|August 10, 2024
概括
用囊性纤维化转膜导电调节剂 (CFTR-T) 治疗可显著降低CF患者的恶化和改善肺功能 (FEV1). 这项研究提供了对中东欧CFTR-T疗效的首次分析.
科学领域:
- 肺部病理学 肺部病理学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 囊性纤维化 (CF) 是一种遗传性疾病,对寿命有重大影响.
- CFTR调制剂 (CFTR-T) 代表了CF患者的新型治疗方法.
- CFTR-T有可能改变预后指标,如恶化频率和FEV1.
研究的目的:
- 分析85名CF患者的恶化发生率和螺旋计数据.
- 为了评估CFTR-T治疗开始后一年的变化.
- 介绍CFTR-T在中东欧地区疗效的首次分析.
主要方法:
- 螺旋计和恶化数据的回顾性分析.
- 包括85名成年CF患者,在2022年中期开始CFTR-T.
- 在波兹纳的CF中心进行数据收集和分析.
主要成果:
- 由于严重恶化的住院率从每名患者/年的1.25下降到0.21.
- 门诊性恶化减少了66%.
- 平均FEV1%增加了9.60% (绝对值,460毫升),即使在严重阻塞组中也有所改善. 此外,FVC%也大幅增加.
结论:
- 一年CFTR-T治疗显示出严重恶化率和FEV1值的显著改善.
- 这些发现凸显了CFTR调节器对CF关键预后标志物的积极影响.
- 需要进一步长期观察,以评估持续的益处和对生活质量和生存的影响.
相关概念视频
Cystic Fibrosis: Management
150
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
150
Cystic Fibrosis: Pathogenesis
201
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
201
Antiasthma Drugs: Leukotriene Modifiers
267
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
267
COPD: Management Using Bronchodilators and Corticosteroids
192
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
192
Drugs Used in Lower Respiratory Disorders: Overview
383
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
383
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
232
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
232


